This research highlights the genetic basis of food fussiness in children, with over 70% of influence from genes, informing strategies for dietary interventions.
Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial
Combining the novel anti-TIGIT monoclonal antibody tiragolumab with atezolizumab (Tecentriq) to treat PD-L1-positive recurrent cervical cancer didn’t improve overall response rate in the phase II